Readressing the role of toll-like receptor-4 alleles in inflammatory bowel disease: Colitis, smoking, and seroreactivity

Digestive Diseases and Sciences

Volumn 58, Issue 2, 2013, Pages 371-380

  Manolakis, Anastassios C ^a   Kapsoritakis, Andreas N ^a   Kapsoritaki, Anastasia ^b   Tiaka, Elisavet K ^a   Oikonomou, Konstantinos A ^a   Lotis, Vassilis ^a   Vamvakopoulou, Dimitra ^a   Davidi, Ioanna ^a   Vamvakopoulos, Nikolaos ^c   Potamianos, Spyros P ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b AMALIA FLEMING GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF THESSALY   (Greece)

Author keywords

Inflammatory bowel disease; Polymorphisms; Serology; Smoking; Toll like receptor 4

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CORTICOSTEROID; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR INHIBITOR; CHITOBIOSE; DISACCHARIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LAMINARIBIOSE; MANNAN; MANNOBIOSE; TLR4 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; DISEASE DURATION; DNA POLYMORPHISM; ENTERITIS; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC PREDISPOSITION; GENOTYPE; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCOLITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SMOKING; SMOKING HABIT; ULCERATIVE COLITIS; BLOOD; EPIDEMIOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; SACCHAROMYCES CEREVISIAE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; CROHN DISEASE; DISACCHARIDES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MANNANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SACCHAROMYCES CEREVISIAE; SEROEPIDEMIOLOGIC STUDIES; SMOKING; TOLL-LIKE RECEPTOR 4; YOUNG ADULT;

MLCS; MLOWN;

EID: 84876324832     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2348-4     Document Type: Article

References (54)

1. Baumgart DC. What's new in inflammatory bowel disease in 2008? World J Gastroenterol. 2008;14:329-330.
2. Rodriguez-Bores L, Fonseca GC, Villeda MA, et al. Novel genetic markers in inflammatory bowel disease. World J Gastroenterol. 2007;13:5560-5570.
3. Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The Toll-like receptor (TLR)-4 Asp299Gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut. 2004;53:987-992.
4. Torok HP, Glas J, Tonenchi L, et al. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol. 2004;112:85-91.
5. De Jager PL, Franchimont D, Waliszewska A, et al. The role of the toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun. 2007;8:387-397.
6. Browning BL, Huebner C, Petermann I, et al. Has Toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol. 2007;102:2504-2512.
7. Brand S, Staudinger T, Schnitzler F, et al. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis. 2005;11:645-652.
8. De Ridder L, Weersma RK, Dijkstra G, et al. Genetic susceptibility has a more important role in pediatric-onset Crohn's disease than in adult-onset Crohn's disease. Inflamm Bowel Dis. 2007;19:317-320.
9. Braat H, Stokkers P, Hommes T, et al. Consequence of function Nod2 and Tlr4 mutations on gene transcription in Crohn's disease patients. J Mol Med. 2005;83:601-605.
10. Fries W, Renda MC, Lo Presti MA, et al. Intestinal permeability and genetic determinants in patients, first-degree relatives, and controls in a high-incidence area of Crohn's disease in Southern Italy. Am J Gastroenterol. 2005;100:2730-2736.
11. Hume GE, Fowler EV, Doecke J, et al. Novel NOD2 haplotype strengthens the association between TLR4 Asp299gly and Crohn's disease in an Australian population. Inflamm Bowel Dis. 2008;14:585-590.
12. Oostenbrug LE, Drenth JP, de Jong DJ, et al. Association between Toll-like receptor 4 and inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:567-575.
13. Ouburg S, Mallant-Hent R, Crusius JB, et al. The Toll-like receptor 4 (TLR4) Asp299Gly polymorphism is associated with colonic localization of Crohn's disease without a major role for the Saccharomyces cerevisiae manna-LBP-CD14-TLR4 pathway. Gut. 2005;54:439-440.
14. Baumgart DC, Buning C, Geerdts L, et al. The c.1-260C>t promoter variant of CD14 but not the c.896A>G (p.D299G) variant of Toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease. Digestion. 2007;76:196-202.
15. Lakatos PL, Altorjay I, Szamosi T, et al. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis. 2009;15:365-374.
16. Arnott ID, Ho GT, Nimmo ER, et al. Toll-like receptor 4 gene in IBD: further evidence for genetic heterogeneity in Europe. Gut. 2005;54:308.
17. Rigoli L, Romano C, Caruso RA, et al. Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease. World J Gastroenterol. 2008;14:4454-4461.
18. Hong L, Leung E, Fraser AG, et al. TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort. J Gastroenterol Hepatol. 2007;22:1760-1766.
19. Henckaerts L, Pierik M, Joossens M, et al. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut. 2007;56:1536-1542.
20. Ferwerda B, McCall MB, Verheijen K, et al. Functional consequences of toll-like receptor 4 polymorphisms. Mol Med. 2008;14:346-352.
21. Ferwerda B, McCall MB, Alonso S, et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci USA. 2007;104:16645-16650.
22. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050-1059.
23. Kim JJ, Sears DD. TLR4 and insulin resistance. Gastroenterol Res Pract. 2010. Available at http://www.hindawi.com/journals/grp/2010/212563. Accessed January 5, 2012.
24. Shen X, Shi R, Zhang H, et al. The Toll-like receptor 4 D299G and T399I polymorphisms are associated with Crohn's disease and ulcerative colitis: a meta-analysis. Digestion. 2010;81:69-77.
25. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis. 2010;16:1583-1597.
26. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
27. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-86.
28. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the working party for the world congresses of gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8-15.
29. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19:5-36.
30. Satra M, Vamvakopoulou DN, Sioutopoulou DO, et al. Sequence-based genotyping HPV L1 DNA&RNA transcripts in clinical specimens. Pathol Res Pract. 2009;205:863-869.
31. Eckmann L. Innate immunity. In: Johnson LR, Barrett KE, Ghishan FK, eds. Physiology of the gastrointestinal tract, vol. 2. Amsterdam: Elsevier; 2006:1033-1066.
32. Arseneau KO, Tamagawa H, Pizzaro TT, et al. Innate and adaptive immune responses related to IBD pathogenesis. Cur Gastroenterol Rep. 2007;9:508-512.
33. Hadley C. Should auld acquaintance be forgot. EMBO Rep. 2004;5:1122-1124.
34. Himmel ME, Hardenberg G, Piccirillo CA, et al. The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology. 2008;125:145-153.
35. Fukata M, Abreu MT. TLR4 signalling in the intestine in health and disease. Biochem Soc Trans. 2007;35:1473-1478.
36. Torchinsky MB, Garaude J, Martin AP, et al. Innate immune recognition of infected apoptotic cells directs T(H)17 cell differentiation. Nature. 2009;458:78-82.
37. Fukata M, Chen A, Klepper A, et al. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology. 2006;131:862-877.
38. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cel. 2004;118:229-241.
39. Fukata M, Michelsen KS, Eri R, et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol. 2005;288:G1055-G1065.
40. Ali S, Tamboli CP. Advances in epidemiology and diagnosis of inflammatory bowel diseases. Cur Gastroenterol Rep. 2008;10:576-584.
41. Rallabhandi P, Bell J, Boukhvalova MS, et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol. 2006;177:322-332.
42. Prohinar P, Rallabhandi P, Weiss JP, et al. Expression of functional D299G. T399I polymorphic variant of TLR4 depends more on coexpression of MD-2 than does wild-type TLR4. J Immunol. 2010;184:4362-4367.
43. Manolakis AC, Kapsoritakis AN, Tiaka EK, et al. Impact of TLR-4 polymorphisms on circulating levels of antibodies against Helicobacter pylori. Helicobacter. 2010;15:481-482.
44. Frolova L, Drastich P, Rossmann P, et al. Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis. J Histochem Cytochem. 2008;56:267-274.
45. Deng J, Ma-Krupa W, Gewirtz AT, et al. Toll-like receptors 4 and 5 induce distinct types of vasculitis. Circ Res. 2009;104:488-495.
46. Liu Y, Zhang Z, Wang L, et al. TLR4 monoclonal antibody blockade suppresses dextran-sulfate-sodium-induced colitis in mice. J Gastroenterol Hepatol. 2010;25:209-214.
47. Ungaro R, Fukata M, Hsu D, et al. A novel Toll-like receptor antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G1167-G1179.
48. Savoye G, Lerebours E. Toll-Like Receptor-4 signaling: a possible candidate pathway to support tobacco smoking effects in ulcerative colitis. Am J Gastroenterol. 2008;103:2947-2948.
49. Bessa J, Bachmann MF. T cell-dependent and -independent IgA responses: role of TLR signaling. Immunol Invest. 2010;39:407-428.
50. Abreu M. Toll-like receptor signaling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol. 2010;10:131-134.
51. Heimesaat MM, Fischer A, Siegmund B, et al. Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4. PLoS ONE. 2007;2:e662.
52. Heimesaat MM, Fischer A, Jahn HK, et al. Exacerbation of murine ileitis by Toll-like receptor 4 mediated sensing of lipopolysaccharide from commensal Escherichia coli. Gut. 2007;56:941-948.
53. McCarthy MI, Zeggini E. Genome-wide association studies in type 2 diabetes. Curr Diab Rep. 2009;9:164-171.
54. McCarthy MI, Hirschhorn JN. Genome-wide association studies: past, present and future. Hum Mol Genet. 2008;17:R100-R101.